In April 2016, an FDA committee voted not to recommend acceptance of eteplirsen, a drug designed to treat muscular dystrophy. In September, however, the FDA did approve the drug, following a heated internal debate.
In April 2016, an FDA committee voted not to recommend acceptance of eteplirsen, a drug designed to treat muscular dystrophy. In September, however, the FDA did approve the drug, following a heated internal debate.
Sign up for our weekly newsletter and unlock one more article for free.
View our Privacy Policy
Want more?
Keep reading for as low as $1.99!
Already a subscriber?
Find my Subscription
Save up to 40% off the cover price when you subscribe to Discover magazine.